[12].AHA 2024. Exploring Provider Hesitancy in Prescribing SGLT2 Inhibitor for Acute Heart Failure Patients: Insights from a Single-Center Teaching Hospital Survey. AHA 2024. [13].John J V McMurray, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Me...
2022年2月28日,来自荷兰格罗宁根大学心内科的Adriaan A. Voors等人在Nature Medicine上发表了题为The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial的临床试验报告,证明因急性心竭而住院的患者也可以从empagliflozin治疗中获取临床收益。 在这项双盲临床...
The latest findings from the EMPA-REG OUTCOME trial show a 34% reduction in hospitalization for heart failure or cardiovascular death in patients receiving empagliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, compared with placebo. These outstanding results call for discussion of the ...
同时也对心血管患者有益,特别是心力衰竭(heart failure,HF)患者,在射血分数降低HF(heart failure with reduced ejection fraction,HFrEF)和射血分数保留HF(heart failure with preserved ejection fraction,HFpEF)患者中,抑制SGLT2均可降低心血管死亡和住院的风险[1]。SGLT2...
(HFrEF), did not achieve statistically significant benefits, though in many studies their benefit was close to significance which was eventually achieved in a meta-analysis.3After being successfully tested in HFrEF, sodium...
EffectsofEmpagliflozinonSymptoms,PhysicalLimi- tationsandQualityofLifeinPatientsHospitalizedfor Acute Heart Failure-Results From the EMPULSE Trial[J].Circulation,2022. [42]XieY,BoweB,GibsonAK,etal.ClinicalImplications ofEstimated GlomerularFiltration RateDipFollow- ing Sodium-Glucose Cotransporter-2Inhibitor...
[2]The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27: 1954-1960.[3]高秀芳，李勇，葛均波，等. 改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议. 中国循环杂志, 2020, 35: 231-238.转载：请标明“...
[4] Voors AA, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial[J]. Nat Med. 2022 Mar;28(3):568-574.
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial Article Open access 28 February 2022 Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved Article ...
Reference Wahinya M, Khan Z. Sodium-glucose contrasporter-2 (SGLT2) inhibitor therapy for the primary and secondary prevention of heart failure on patients with and without type 2 diabetes mellitus: a systemic review. Cureus. 15(4): e37388. doi:10.7759/cureus.37388Related...